To gain insight into the dynamics of the therapy-responsive T cell subsets, we longitudinally followed the CD431B11+, NKG2A+, and KLRG1+ T cell subsets in the blood circulation of ICT-treated MC-38 tumor-bearing mice. This evidence concerns the gene KLRG1 and neoplasm.